As included in previous update, I am now CRPC. Uro has added Cosodex (50mg per day) to my Zolodex and referred me to MO. MO advises that I have 2 options - start chemo immediately, or go on AKT inhibitor clinical trial. Trial is Abariterone + prednisone + AKT inhibitor, or Abariterone + prednisone + placebo. I see MO next week and need to confirm approach.
Clinical trials are really important but 2 things I need to think about:
- I am only 55 and I hopefully have many years left. I need to chose the treatment path that is best for me.
- the clinical trial is randomised of course and ther is only 50% change that I get the AKT inhibitor.
Do any men here have experience with AKT inhibitor trials? I found some references to AKT pathways in Parrick's excellent posts about supplements but can't find any references to clinical trials? Hmm, what to do?
Written by
Hazard
To view profiles and participate in discussions please or .
Do you know how what the dosing of the AKT inhibitor will be ? I would love to learn more.
I really enjoy Patrick's excellent posts. My challenge is determining dosages for my husband. We are careful and only add one thing at a time and see how it goes.
Natural substances such as apigenin may inhibit Akt. Typically, they can be taken at high doses without side effects. I have no idea how they compare to industrial strength MK2206 & AZD5363. I tend to think of supplements as having incremental benefit & possible synergy - not heavy hitters, necessarily, but useful for slowing progression.
Of the 3 MK2206 trials, 2 are "Active, not recruiting", while the 3rd has "Completed". [2]
Of the 5 AZD5363 trials, 4 are "Recruiting", but I don't see yours there. [3]
Does it involve a different drug?
Anyway, I thought I would look at PubMed studies for MK2206 [4] & AZD5363 [5].
[4a] A Phase I Trial of Combined Ridaforolimus and MK-2206 in Patients with Advanced Malignancies.
[4b] Interrogating two schedules of the AKT inhibitor MK-2206 in patients with advanced solid tumors incorporating novel pharmacodynamic and functional imaging biomarkers.
[4c] Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors.
[5a] ProCAID: a phase I clinical trial to combine the AKT inhibitor AZD5363 with docetaxel and prednisolone chemotherapy for metastatic castration resistant prostate cancer.
"MO advises that I have 2 options" - presumably means locally. There are other clinical trials.
Is there any update on the Akt inhibitor? My Research Doc mentioned this in passing today. I was wondering if you heard any news on it since this port is a year old.
Thanks Patrick, as per my reply to SoftWareMum, I am on holiday this week, back in Melbourne (Australia) next week, I will get more then. Trial is at Peter MacCallum in Melb.
my husband started on casodex and lupron the day of diagnosis, then 42 IMRT radiation treatments a few months down the road. he was 57 and is still here at age 69. after all of the hormone ablation drugs i feel the casodex lasted longest...abiraterone, second with side effects from prednisone (bleeding under the skin so easily) and last AND LEAST xtandi. between abiraterone and xtandi they tried chemo with no result.
In the beginning, we went to Dana-Farber to see about a clinical trial of high dose docetaxel at the onset. the clinicians (as opposed to the researchers) talked us out of participating, but, of course, now, it seems to be the treatment of choice.
Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.
Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.
Blood transfusions dependent/clinical trials.
Treatment naïve and clinical trials
PARP inhibitors - which one?
Clinical trial / study: BRCA mutations
